NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ — NeuShen Therapeutics (the…
Körber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking
LONDON, May 8, 2024 /PRNewswire/ — The new Competitive Assessment by global…